drugset
drugset / Trial / NCT05575973

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

NCT05575973 ↗

Phase 2 Unknown 55 enrolled Jianfeng Zhou CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide in the treatment of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).

Timeline

Start
2022-10-10
Primary completion
2025-07
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous
Background Lenalidomide Other / unclassified 25 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma